公开(公告)号：US10398651B2

公开(公告)日：2019-09-03

申请号：US15624303

申请日：2017-06-15

Applicant: Purdue Research Foundation

Inventor： Yoon Yeo ,  Joonyoung Park ,  Bo Sun

IPC: A61K9/16 ,  A61K31/337 ,  A61K9/00 ,  A61K47/10 ,  A61K9/51

Abstract: A carrier free nanoparticle formulation with good circulation stability is made for anticancer drug delivery. Nanocrystals crystallized in the medium containing Pluronic F-127 then coated with albumin (Cim-F-Alb) had the smallest size and the most native albumin, and showed most favorable cell interaction profiles and better stability than commercial albumin based Abraxane formulation, while maintaining comparable cytotoxicity to those of Abraxane and solvent-dissolved paclitaxel (PTX).

公开(公告)号：US20170360709A1

公开(公告)日：2017-12-21

申请号：US15624303

申请日：2017-06-15

Applicant: Purdue Research Foundation

Inventor： Yoon Yeo ,  Joonyoung Park ,  Bo Sun

IPC: A61K9/16 ,  A61K31/337

CPC classification number: A61K9/167 ,  A61K9/0019 ,  A61K9/1641 ,  A61K9/1652 ,  A61K9/1658 ,  A61K9/5161 ,  A61K9/5169 ,  A61K9/5192 ,  A61K31/337 ,  A61K47/10

Abstract: A carrier free nanoparticle formulation with good circulation stability is made for anticancer drug delivery. Nanocrystals crystalized in the medium containing Pluronic F-127 then coated with albumin (Cim-F-Alb) had the smallest size and the most native albumin, and showed most favorable cell interaction profiles and better stability than commercial albumin based Abraxane formulation, while maintaining comparable cytotoxicity to those of Abraxane and solvent-dissolved paclitaxel (PTX).